Bridger Management’s Akero Therapeutics AKRO Stock Holding History

Bridger Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-101,500	Closed	-$5.13M	–	31
2023 Q3	$5.13M	Buy	+101,500	New	+$4.73M	1.88%	18

Other funds holding AKRO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bridger Management's AKRO Position: Q4 2023 in Review

Bridger Management sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 101,500 shares — an estimated $5.13M sold.

Bridger Management first reported a position in AKRO in Q3 2023 and held it in 1 quarter. The position peaked at $5.13M in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

Bridger Management reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
Bridger Management sold 101,500 Akero Therapeutics shares in Q4 2023, an estimated $5.13M.
Bridger Management first reported a position in Akero Therapeutics in Q3 2023 and held it in 1 quarter.
Bridger Management's Akero Therapeutics position peaked at $5.13M in Q3 2023.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Bridger Management's 13F filing for Q4 2023, filed 14 Feb 2024.